Spots Global Cancer Trial Database for Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Official Title: Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Study ID: NCT04316013
Study Description
Brief Summary: VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.
Detailed Description: VAPOR-C is a pragmatic, event-driven, randomised controlled trial, with a single blind 2x2 factorial design for sevoflurane/propofol and for intravenous lidocaine infusion / no lidocaine infusion. This trial is designed to test for superiority in disease free survival (DFS) of propofol (total intravenous anaesthesia -TIVA) over sevoflurane (inhalational volatile anaesthesia) and intravenous lidocaine over no lidocaine in patients undergoing surgery for colorectal or non small cell lung cancer (NSCLC). The combination of two cancer types will help address the need to demonstrate the effects of anaesthetic technique across cancers to inform generalisable anaesthesia guidelines. Both NSCLC and colorectal cancer are important for this study due to high incidence rate, many longer-term survivors, and importantly the high risk of local or distant recurrence despite complete surgical resection. In addition, the study will collect additional data in a nested cohort related to the exploratory objectives. The study aims to recruit 3,500 patients in Australia, New Zealand, Canada, United States and Europe.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cleveland Clinic, Cleveland, Ohio, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
The University of Texas MD Anderson Cancer Centre, Houston, Texas, United States
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
Prince of Wales Hospital, Randwick, New South Wales, Australia
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
Mackay Base Hospital, Mackay, Queensland, Australia
RedCliffe Hospital, Redcliffe, Queensland, Australia
Rockhampton Hospital, Rockhampton, Queensland, Australia
Gold Coast University Hospital, Southport, Queensland, Australia
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Royal Hobart Hospital, Hobart, Tasmania, Australia
Ballarat Base Hospital, Ballarat Central, Victoria, Australia
Box Hill Hospital, Box Hill, Victoria, Australia
Northern Hospital, Epping, Victoria, Australia
St Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia
Western Health Footscray Hospital, Footscray, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
The Alfred Hospital, Melbourne, Victoria, Australia
The Royal Melbourne Hospital, Parkville, Victoria, Australia
Goulburn Valley Health, Shepparton, Victoria, Australia
Northeast Health, Wangaratta, Wangaratta, Victoria, Australia
North Shore Hospital, Auckland, , New Zealand
Auckland City Hospital, Auckland, , New Zealand
Contact Details
Name: Bernhard Riedel, MB.ChB
Affiliation: Peter MacCallum Cancer Centre, Australia
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
